Suboxone Film lawsuit update

Verified snapshot

The facts that anchor this dossier

Suboxone film is an important treatment for opioid use disorder, and FDA says its benefits outweigh the dental risks. MDL 3092 asks a different question: whether the film's makers adequately warned about alleged dental erosion and decay.

Federal proceeding

MDL 3092

Northern District of Ohio before Judge J. Philip Calabrese.

Actions pending

1,832

JPML count as of July 1, 2026; 1,908 actions are listed historically.

FDA warning

January 12, 2022

FDA required dental-risk warnings for buprenorphine medicines dissolved in the mouth.

Core allegation

Dental erosion and decay

Plaintiffs allege inadequate warnings involving brand-name Suboxone film; defendants contest the claims.

Treatment caution

Do not stop abruptly

FDA stresses that buprenorphine's benefits outweigh the dental risk and that treatment changes require clinical guidance.

Documented chronology

How the litigation reached this point

Two truths have to be held together

Suboxone film contains buprenorphine and naloxone and is placed under the tongue or inside the cheek. Buprenorphine is a partial opioid agonist used to treat opioid use disorder. FDA emphasizes that it reduces withdrawal and craving and can help sustain recovery and reduce overdose risk. The agency's 2022 dental warning explicitly said the benefits of buprenorphine clearly outweigh the reported dental risks.

At the same time, FDA identified a meaningful safety signal with medicines containing buprenorphine that dissolve in the mouth. The agency reviewed 305 reported dental cases, 131 classified as serious, including cavities, oral infections, and tooth loss. Twenty-six reports involved people with no previous dental problems; 71 mentioned extraction. FDA also cautioned that spontaneous reports cannot establish how often these events occur. The median reported time to diagnosis was about two years, though some problems were reported much earlier.

This is why 'stop the medicine' is not a responsible takeaway. Abrupt discontinuation can destabilize opioid-use-disorder treatment and increase relapse and overdose risk. The better response is preventive dental care, correct after-dose oral care, and coordinated treatment decisions with the prescriber and dentist.

What FDA now tells patients and clinicians

Current Suboxone labeling has a dedicated dental-adverse-events warning. It describes reported caries, tooth fracture, tooth loss, abscess or infection, erosion, fillings falling out, and restorative treatment. Prescribers are told to ask about oral health, refer patients for dental care soon after starting therapy, and encourage regular checkups. Dentists are advised to perform a baseline assessment and develop a caries-prevention plan.

After the film has completely dissolved, the label advises gently rinsing the teeth and gums with water and swallowing the water. Patients should wait at least one hour before brushing. The waiting period is intended to avoid brushing immediately after oral exposure, when the tooth surface may be vulnerable. These instructions supplement ordinary dental care; they do not guarantee that a problem will or will not occur.

The label also distinguishes reported postmarketing events from clinical-trial rates. Voluntary reports come from a population of uncertain size and cannot reliably estimate frequency or prove a causal relationship. That limitation should appear beside the warning, not be buried beneath it.

What the research adds

A 2022 cohort analysis compared new users of sublingual buprenorphine/naloxone with transdermal buprenorphine and injectable naltrexone using insurance claims. It reported more dental adverse events in the sublingual group. Like other database studies, it relied on coded diagnoses and treatment data and could not randomize formulation choice, diet, smoking, dry mouth, baseline dental health, access to dentistry, or duration of opioid use.

A newer retrospective cohort published in 2026 included 14,495 adults with opioid use disorder. Dental events occurred in 2.17% of oral-buprenorphine users and 1.66% of controls, with an adjusted hazard ratio of 1.36. That is evidence of an association in the studied data, not proof that film caused a particular cavity. It also grouped oral buprenorphine exposure more broadly than a product-liability court may permit.

The clinical context matters. Randomized and observational treatment studies show that buprenorphine can retain patients in treatment and reduce illicit opioid use. A dental-risk discussion that erases those benefits can cause harm. The legally relevant warning question and the clinically relevant treatment question overlap, but they are not the same decision.

What MDL 3092 is doing now

The JPML centralized the litigation in February 2024 after finding shared factual questions about the alleged propensity of Suboxone film to cause dental erosion and decay, product development and labeling, and the adequacy of warnings. The court's public MDL page collects case-management orders. The census process asks for proof of brand-name Suboxone film use and dental injury after use, among other records. Those are litigation-screening requirements, not a public promise that a claim will survive or be paid.

The amended bellwether protocol creates progressively narrower groups: a record-collection pool, a core-discovery pool, and a trial-selection pool. A March 2026 schedule set steps for selecting 50 core-discovery cases during June and July 2026. Bellwether selection lets the parties test recurring proof with full records; it does not turn the MDL into a class action.

On July 1, 2026, the JPML counted 1,832 pending actions and 1,908 historical actions. The small difference suggests most historically associated actions remained pending on that date, but it says nothing about merits, product proof, dental causation, or eventual resolution.

The record trail that matters

Pharmacy records can show whether the dispensed product was brand-name Suboxone film, a generic film, a tablet, or another formulation. Prescriber notes establish indication, dose, and duration. Dental charts can show baseline condition, caries pattern, periodontal disease, xerostomia, fractures, extractions, restorative work, and when problems first appeared. Photographs and radiographs may help a dentist interpret progression.

Other factors are not moral judgments; they are clinical variables. Tobacco use, diet, dry mouth from other medicines, reflux, diabetes, oral hygiene, access to dental care, and prior substance use can affect dental health. A rigorous review accounts for them rather than assuming a person's history either proves or disproves causation.

Anyone currently taking buprenorphine should discuss concerns with the treating clinician and dentist without interrupting therapy on their own. A legal review, if desired, is separate and depends on product proof, injury chronology, state law, and procedural deadlines. This dossier cannot determine qualification or forecast compensation.

Reader questions

Frequently asked questions